Celyad: First “Clinical Validity” For NKR CAR T-Cells – Investing.com
Labiotech.eu (blog) |
Celyad: First “Clinical Validity” For NKR CAR T-Cells
Investing.com Celyad SA (NASDAQ:CYAD) has reported a complete morphological leukaemia-free status (MFLS) response in acute myeloid leukaemia (AML) in the NKR CAR T-cell THINK study. Given that spontaneous remission in refractory/relapsed AML is extremely … Belgian Biotech's Leukemia CAR–T Treatment Leaves Patient Cancer-Free |
